Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06050317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Aug 18, 2026 to Dec 18, 2026
    • Eligibility criteria expanded, about 15 words
    • Publications: details revised at 23 of 23 entries
  2. Re-verified, no change to tracked fieldsv4
  3. Interventions: Sintilimab Plus mFFN and Radiation (Drug) to Sintilimab Plus mFFN or NALIRIFOX and Radiation (Drug)
    • Publications: details revised at 4 of 23 entries
    v3
  4. Publications: details revised at 4 of 23 entriesv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
Trial Details
NCT Number NCT06050317
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions
(from sponsor)		 Pancreas Cancer
Related terms Pancreatic Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov